In the present study, we analyzed the prognostic factors of patients with DLBCL who received standard 4–6 cycles of R-CHOP, and we further evaluated the clinical significance of upfront ASCT in higher risk patients who were in their first remission. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.